Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to facilitate patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in four simple steps:
Radboud university medical center and Quirem Medical today signed an agreement for joint research. The agreement includes several existing and future projects based on small
In their study, Smits et al. showed that QuiremScout® is a superior predictor of intrahepatic dose distribution compared to Tech-99m-MAA. The results of their study
Deventer, August 7, 2019 – Today a first clinical QuiremScout® patient procedure took place with radioactive holmium-166 microspheres that were activated at the NRG reactor
On July 31, Quirem Medical received with great pleasure Mr. Zhang Guosheng – the Economic & Commercial Counsellor from the Embassy of the People’s Republic
McMaster University and Quirem Medical announce the first clinical case using the McMaster Nuclear Reactor Deventer (The Netherlands), Hamilton (Canada), 6th of June 2019 McMaster
The first QuiremScout® cases have been successfully performed by clinical teams in Dresden and Pisa last week. We congratulate the clinical teams, and everyone involved!
Terumo Europe today announced that QuiremScout® has received CE mark, making it available as the first and only CE marked product indicated for SIRT work
We are pleased to announce that the Radboudumc in Nijmegen has treated its first patient with QuiremSpheres®. This milestone has been made possible by an
On December 11th, hospital Universitario Germans Trias i Pujol located in Barcelona has successfully performed their first QuiremSpheres® treatment. This marks yet another QuiremSpheres® SIRT
On November 21st 2018, the first QuiremSpheres® procedure in Iberia was performed in Lisbon, Portugal. A patient, suffering from hepatocellular carcinoma, was successfully treated with
Telephone: +31 85 0404170
E-mail: info.quirem@terumo-europe.com